NASDAQ:PIRS - Nasdaq - US7207952026 - Common Stock - Currency: USD
Overall PIRS gets a fundamental rating of 3 out of 10. We evaluated PIRS against 556 industry peers in the Biotechnology industry. While PIRS seems to be doing ok healthwise, there are quite some concerns on its profitability. PIRS is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -77.74% | ||
ROE | -98.06% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -8.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.82 | ||
Quick Ratio | 4.82 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
13.6
-2.53 (-15.69%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 80.17 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 6.66 | ||
P/tB | 6.66 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -77.74% | ||
ROE | -98.06% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 0.68% | ||
Cap/Sales | 0.96% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.82 | ||
Quick Ratio | 4.82 | ||
Altman-Z | -8.87 |